UBS has given Merck KGaA a 'Buy' rating and set a target price of 190 euros for the company.
This decision was made after the recent capital market day, which reinforced UBS's positive outlook on the stock's attractive valuation.
Analyst Matthew Weston emphasized the event's confirmation of the company's strong market position.
The study containing this assessment was published on October 22, 2024, at 19:15 GMT.
Investors and market participants are advised to consider this rating when evaluating their positions in Merck KGaA.
More information about potential conflicts of interest related to the analyst firm can be found on the official disclosure website.